{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:42:00Z","timestamp":1794440520754,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200999) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200949). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88\u22121.79;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73\u22122.38;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.44). Grade 3\u22124 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p\u2009&lt;\u20090.001). In conclusion, while adjuvant nDC treatment in stage IIIB\/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-45358-0","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:03:02Z","timestamp":1708668182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Kalijn F.","family":"Bol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-8365","authenticated-orcid":false,"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bloemendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"van Willigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hins-de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"de Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J. H.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjitske","family":"Duiveman-de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A. M.","family":"Olde Nordkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom G. M.","family":"van Oorschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlijn J.","family":"Popelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Pots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Scharenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy W. M. M.","family":"van de Rakt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"de Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmy S.","family":"van Meeteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Croockewit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-1036","authenticated-orcid":false,"given":"Bouke J.","family":"Koeneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-8416","authenticated-orcid":false,"given":"Jeroen H. A.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-5229","authenticated-orcid":false,"given":"Inge M. N.","family":"Wortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Angerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareke","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Dzionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk J.","family":"van Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna E. M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes J.","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger H. T.","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn F.","family":"Boomsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H. J.","family":"Aarntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4287","authenticated-orcid":false,"given":"Theo J. M.","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-9212","authenticated-orcid":false,"given":"Carl G.","family":"Figdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9668","authenticated-orcid":false,"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0459-9458","authenticated-orcid":false,"given":"Johannes","family":"Textor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-9119","authenticated-orcid":false,"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4040","authenticated-orcid":false,"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"45358_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252 (1998).","journal-title":"Nature"},{"key":"45358_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265\u2013277 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"45358_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","volume":"42","author":"I Baraibar","year":"2019","unstructured":"Baraibar, I., Melero, I., Ponz-Sarvise, M. & Castanon, E. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 42, 281\u2013294 (2019).","journal-title":"Drug Saf."},{"key":"45358_CR4","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F. & Berneman, Z. N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257\u2013e267 (2014).","journal-title":"Lancet Oncol."},{"key":"45358_CR5","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.4049\/jimmunol.170.6.3306","volume":"170","author":"A Soruri","year":"2003","unstructured":"Soruri, A. et al. IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J. Immunol. 170, 3306\u20133314 (2003).","journal-title":"J. Immunol."},{"key":"45358_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1189\/jlb.0105052","volume":"78","author":"K Breckpot","year":"2005","unstructured":"Breckpot, K. et al. Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J. Leukoc. Biol. 78, 898\u2013908 (2005).","journal-title":"J. Leukoc. Biol."},{"key":"45358_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1096\/fsb2fj000508hyp","volume":"15","author":"M Thurnher","year":"2001","unstructured":"Thurnher, M., Zelle-Rieser, C., Ramoner, R., Bartsch, G. & Holtl, L. The disabled dendritic cell. FASEB J. 15, 1054\u20131061 (2001).","journal-title":"FASEB J."},{"key":"45358_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","volume":"5","author":"F Wimmers","year":"2014","unstructured":"Wimmers, F., Schreibelt, G., Skold, A. E., Figdor, C. G. & De Vries, I. J. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front. Immunol. 5, 165 (2014).","journal-title":"Front. Immunol."},{"key":"45358_CR9","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2001-11-0097","volume":"100","author":"KP MacDonald","year":"2002","unstructured":"MacDonald, K. P. et al. Characterization of human blood dendritic cell subsets. Blood 100, 4512\u20134520 (2002).","journal-title":"Blood"},{"key":"45358_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","volume":"22","author":"G Schreibelt","year":"2016","unstructured":"Schreibelt, G. et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin. Cancer Res. 22, 2155\u20132166 (2016).","journal-title":"Clin. Cancer Res."},{"key":"45358_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","volume":"73","author":"J Tel","year":"2013","unstructured":"Tel, J. et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73, 1063\u20131075 (2013).","journal-title":"Cancer Res."},{"key":"45358_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","volume":"7","author":"H Westdorp","year":"2019","unstructured":"Westdorp, H. et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J. Immunother. Cancer 7, 302 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"45358_CR13","doi-asserted-by":"publisher","first-page":"2015113","DOI":"10.1080\/2162402X.2021.2015113","volume":"11","author":"M Bloemendal","year":"2022","unstructured":"Bloemendal, M. et al. Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients. Oncoimmunology 11, 2015113 (2022).","journal-title":"Oncoimmunology"},{"key":"45358_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdj138","volume":"17","author":"D Schadendorf","year":"2006","unstructured":"Schadendorf, D. et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17, 563\u2013570 (2006).","journal-title":"Ann. Oncol."},{"key":"45358_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Eng. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Eng. J. Med."},{"key":"45358_CR16","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"key":"45358_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","volume":"213","author":"TF Gajewski","year":"2006","unstructured":"Gajewski, T. F. et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131\u2013145 (2006).","journal-title":"Immunol. Rev."},{"key":"45358_CR18","doi-asserted-by":"publisher","first-page":"e1191732","DOI":"10.1080\/2162402X.2016.1191732","volume":"5","author":"S Boudewijns","year":"2016","unstructured":"Boudewijns, S. et al. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology 5, e1191732 (2016).","journal-title":"Oncoimmunology"},{"key":"45358_CR19","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1158\/0008-5472.CAN-12-2479","volume":"72","author":"EHJG Aarntzen","year":"2012","unstructured":"Aarntzen, E. H. J. G. et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res. 72, 6102\u20136110 (2012).","journal-title":"Cancer Res."},{"key":"45358_CR20","doi-asserted-by":"publisher","first-page":"e1057673","DOI":"10.1080\/2162402X.2015.1057673","volume":"5","author":"K Bol","year":"2016","unstructured":"Bol, K. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology 5, e1057673 (2016).","journal-title":"OncoImmunology"},{"key":"45358_CR21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont, A. M. et al. Prolonged survival in stage III Melanoma with Ipilimumab Adjuvant Therapy. N. Engl. J. Med. 375, 1845\u20131855 (2016).","journal-title":"N. Engl. J. Med."},{"key":"45358_CR22","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"45358_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N. Engl. J. Med. 377, 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"key":"45358_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant Pembrolizumab versus placebo in resected stage III Melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"45358_CR25","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1245\/s10434-019-07274-2","volume":"26","author":"M Bloemendal","year":"2019","unstructured":"Bloemendal, M. et al. Early recurrence in completely resected IIIB and IIIC melanoma warrants restaging prior to adjuvant therapy. Annl. Surg. Oncol. 26, 3945\u20133952 (2019).","journal-title":"Annl. Surg. Oncol."},{"key":"45358_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"45358_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368\u20131379 (2017).","journal-title":"Ann. Oncol."},{"key":"45358_CR28","doi-asserted-by":"publisher","unstructured":"Alves Costa Stilva, C. et al. Influence of microbiota-associated metabolic reprograming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-024-45357-1 (2024).","DOI":"10.1038\/s41467-024-45357-1"},{"key":"45358_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet. Oncol. 16, 522\u2013530 (2015).","journal-title":"Lancet. Oncol."},{"key":"45358_CR30","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube, A. et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6, e18801 (2011).","journal-title":"PLoS One"},{"key":"45358_CR31","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1158\/0008-5472.CAN-12-2479","volume":"72","author":"EH Aarntzen","year":"2012","unstructured":"Aarntzen, E. H. et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell based vaccination in metastatic melanoma. Cancer Res. 72, 6102\u20136110 (2012).","journal-title":"Cancer Res."},{"key":"45358_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"45358_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal. Transduct Target Ther. 8, 9 (2023).","journal-title":"Signal. Transduct Target Ther."},{"key":"45358_CR34","doi-asserted-by":"publisher","first-page":"e005141","DOI":"10.1136\/jitc-2022-005141","volume":"10","author":"JK Schwarze","year":"2022","unstructured":"Schwarze, J. K. et al. Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J. Immunother. Cancer 10, e005141 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"45358_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40259-018-0277-2","volume":"32","author":"DA Emerson","year":"2018","unstructured":"Emerson, D. A. & Redmond, W. L. Overcoming tumor-induced immune suppression: from relieving inhibition to providing costimulation with T cell agonists. BioDrugs 32, 221\u2013231 (2018).","journal-title":"BioDrugs"},{"key":"45358_CR36","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas, A. et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15, 6267\u20136276 (2009).","journal-title":"Clin. Cancer Res."},{"key":"45358_CR37","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","volume":"34","author":"S Wilgenhof","year":"2016","unstructured":"Wilgenhof, S. et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 34, 1330\u20131338 (2016).","journal-title":"J. Clin. Oncol."},{"key":"45358_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","volume":"9","author":"M Versteven","year":"2018","unstructured":"Versteven, M. et al. Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer. Front. Immunol. 9, 394 (2018).","journal-title":"Front. Immunol."},{"key":"45358_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-017-0458-3","volume":"10","author":"T Achkar","year":"2017","unstructured":"Achkar, T. & Tarhini, A. A. The use of immunotherapy in the treatment of melanoma. J. Hematol. Oncol. 10, 88 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"45358_CR40","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl. J. Med. 376, 2211\u20132222 (2017).","journal-title":"N Engl. J. Med."},{"key":"45358_CR41","doi-asserted-by":"publisher","unstructured":"Textor, J. & Wortel, I. M. jtextor\/trialMinRand: Initial release (v1.0.0). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.10145627 (2023).","DOI":"10.5281\/zenodo.10145627"},{"key":"45358_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock, S. J. & Simon, R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31, 103\u2013115 (1975).","journal-title":"Biometrics"},{"key":"45358_CR43","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1200\/JCO.2005.06.478","volume":"23","author":"IJ de Vries","year":"2005","unstructured":"de Vries, I. J. et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23, 5779\u20135787 (2005).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45358-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:07:56Z","timestamp":1708668476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45358-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45358"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45358-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.F.B.: consultancy fees (all paid to institute) from MSD and Pierre Fabre. A.A.v.d.V.: consultancy fees (all paid to institute) from BMS, MSD, Pierre Fabre, Merck, Pfizer, Novartis, Sanofi, Ipsen, Eisai, Roche. CA\/MBr\/KP\/AD: employees of Miltenyi Biotec. J.W.B.d.G.: received personal fees outside the submitted work from Bristol-Myers Squibb, Roche, Pierre Fabre, Servier, MSD, and Novartis. J.B.A.G.H.: advisory relationships with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celsius Therapeutics, GSK, Immunocore, Ipsen, MSD, Merck Serono, Novartis, Neon Therapeutics, Pfizer, Roche\/Genentech, Sanofi, and Seattle Genetics and has received research grants not related to this paper from Novartis, BMS, MSD, and Neon Therapeutics. W.R.G.: speaker fees from MSD; advisory role (institutional) for Bristol-Myers Squibb and Bayer; research grants (institutional) from Astellas, Bayer, Janssen-Cilag, MSD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1632"}}